ArticleOpen forum infectious diseases2025
The Complex Landscape of Updated Pneumococcal Conjugate Vaccines.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An overview of the clinical development of the 20-valent pneumococcal conjugate vaccine in adults.Human vaccines & immunotherapeutics · 2026Review
- Targeted pneumococcal conjugate vaccination strategies for high-risk children.Human vaccines & immunotherapeutics · 2026Review
- Practical Considerations Shaping Pneumococcal Vaccine Selection: A Multinational Cross-Sectional Survey of Healthcare Professionals.Infectious diseases and therapy · 2026Article
- Future Pneumococcal Vaccines: Shifting from Capsular Polysaccharides to Protein-Based Immunogens.Vaccines · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
Pneumococcus is a major cause of serious infections, especially among vulnerable populations. While pneumococcal conjugate vaccines (PCVs) provide effective protection against disease caused by the included serotypes, a substantial burden of disease remains. Several new PCVs are under development or were recently recommended for use to counteract the remaining disease burden. This had led to complicated policy deliberations on their optimal use in different populations. We discuss how key factors should be considered in any policy decision: serotype coverage of a new PCV, prevalence of the untargeted remaining serotypes, strength of the immune response to the serotypes in a new PCV, potential for PCV evasion, PCV costs, and optimal simultaneous use of PCVs in children and adults. We also suggest the need for robust analyses of available surveillance data and continual monitoring of changes in the pneumococcal serotypes that are responsible for disease and colonization to help decision makers make optimal recommendations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.